SEC Form 4 · accession 0001623919-16-000094
EndoChoice Holdings, Inc. · GI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Rjr Balkcom
Director
Period of report
Nov 22, 2016
Accepted (ET)
Nov 23, 2016 · 10:20 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001623919
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, par value $0.001 per shareF1 | Nov 22, 2016 | D | 21,235 | $8.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3,F2 | $3.32 | Nov 22, 2016 | D | 4,156 | D | — | Jan 24, 2022 | Common stock, par value $0.001 per share | 4,156 | 0 | D |
| Employee Stock Option (right to buy)F3,F2 | $2.83 | Nov 22, 2016 | D | 20,736 | D | — | Dec 16, 2019 | Common stock, par value $0.001 per share | 20,736 | 0 | D |
Explanation of responses
- F1Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer.
- F2Issuer's outstanding stock options, if not yet vested, became fully vested pursuant to the terms and conditions of the Merger.
- F3This option was cancelled pursuant to the Merger in exchange for a cash payment representing the difference between the exercise price of the option and the merger consideration of $8.00 per share.